Clinical trials: Cardiovascular Risk Factor
Cardiovascular Risk Factors, Serious Mental Illness
Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness
This study will determine whether a program where a health coach works with participants on heart healthy behaviors and treatment of risk factors is coordinated with primary care can reduce overall heart disease risk in people…
- Trial name
- IDEAL (NCT02127671)
- Testing
- IDEAL intervention, Control
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- Johns Hopkins University
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Cardiovascular Risk Factor, Stress
Stress-reduction Wellness Program for Midlife Black Women (B-SWELL)
This research study examines the unique cultural and gender-based factors that influence how midlife Black women experience stress and incorporate healthy lifestyle behaviors into daily life.
- Conditions
- Cardiovascular Risk Factor, Stress, Self Efficacy, Depressive Symptoms
- Trial name
- B-SWELL (NCT04404478)
- Testing
- B-SWELL: Midlife Black Women's Stress Reduction Wellness Program, WE: Wellness program for Midlife Black Women
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Obesity, Body Composition
Study of Macronutrients and Heart Disease Risk
The objective of this trial is to examine the long-term effects of a diet low in carbohydrates, as compared to one low in fat, on cardiovascular disease risk factors, including blood pressure (BP), body weight and composition…
- Conditions
- Obesity, Body Composition, Blood Pressure, Cardiovascular Diseases
- Trial name
- MACRO (NCT00609271)
- Testing
- low carbohydrate diet, low fat diet
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Tulane University Health Sciences Center
Hypertension
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular…
- Trial name
- NCT00936208
- Where
- 120 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 3,184 people
- Sponsor
- Boehringer Ingelheim
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Sedentary Behavior, Cardiovascular Risk Factor
Combined Effects of Prolonged Sitting and Mental Stress on the Cardiovascular System
Prolonged sitting may pose a public health risk through its effects on the cardiovascular system, and may lead to impaired whole-body cardiovascular health, which includes both vascular and cerebrovascular function.
- Conditions
- Sedentary Behavior, Cardiovascular Risk Factor, Mental Stress, Cognitive Change
- Trial name
- NCT04207333
- Testing
- Mental Arithmetic Test
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Obesity
Improving Cardiovascular Risk Factors in Black Young Adults
The objectives of the study are to conduct a randomized controlled trial to test the efficacy of the Smartphone intervention on % weight loss and maintaining % weight loss at 6 and 12 months in a sample (N=256) of Black community…
- Trial name
- NCT04412954
- Testing
- Smartphone + Text Messaging with Health Coach
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Growth Hormone Deficiency
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
- Trial name
- NCT00684957
- Testing
- Recombinant Human Growth Hormone, Recombinant Human IGF-1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Cardiovascular Risk Factor, Type2 Diabetes Mellitus
Orange Juice And Sugar Intervention Study
The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.
- Conditions
- Cardiovascular Risk Factor, Type2 Diabetes Mellitus, Insulin Sensitivity, Metabolic Syndrome
- Trial name
- OASIS (NCT03527277)
- Testing
- Naturally-sweetened orange juice, Sugar-sweetened beverage
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
ASCVD, Risk Factor, Cardiovascular
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy…
- Conditions
- ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol
- Trial name
- ORION-11 (NCT03400800)
- Testing
- Inclisiran Sodium
- Where
- 70 sites in Czechia, Germany and 5 more
- Volunteers
- 1,617 people
- Sponsor
- The Medicines Company
Cardiovascular Disease, Coronary Disease
Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors
The purpose of this trial are to pragmatically investigate whether participation in a comprehensive CR (i.e., exercise with education) program in a Latin American MIC results in better functional capacity, cardiovascular risk…
- Trial name
- NCT02575976
- Testing
- comprehensive CR, exercise-based CR, wait list control
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Federal University of Minas Gerais
Cardiovascular Diseases, Cardiovascular Abnormalities
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada.
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Heart Attack, Stroke
- Trial name
- NCT03826914
- Testing
- CardioFlex Q10
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Cardiovascular Risk Factor, Prediabetes
Active You: A Novel Exercise Program for African Americans
Barriers to physical activity (PA) among African Americans (AAs) have been extensively studied, yet there is a paucity of innovative PA interventions designed to address them.
- Conditions
- Cardiovascular Risk Factor, Prediabetes, Overweight and Obesity, Sedentary Behavior
- Trial name
- NCT04280783
- Testing
- The Physical Activity for The Heart (PATH) intervention, Be Active Your Way Booklet
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Stroke (CVA) or TIA, Diabetes
Risk Factors, Costs, and Impacts of ED Boarding
The goal of this observational study is to learn about the risk factors, costs, and operational impacts of emergency department boarding (patients admitted to the hospital but remaining in the emergency department awaiting…
- Conditions
- Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
- Trial name
- NCT07532564
- Where
- United States
- Volunteers
- 30,486 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Cardiovascular Risk Factor, Circadian Dysregulation
Body Weight, Sleep, and Heart Health
A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity.
- Conditions
- Cardiovascular Risk Factor, Circadian Dysregulation, Obesity
- Trial name
- NCT03388788
- Testing
- Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
Cardiovascular Risk Factor
Choline and Cardiometabolic Health
Trimethylamine-N-oxide (TMAO), a metabolite produced by gut microbial metabolism of dietary choline, has recently been causally linked to atherosclerosis in animal models and has been shown to be predictive of cardiovascular…
- Trial name
- NCT04764162
- Testing
- Choline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
- Trial name
- SPIRE-LL (NCT02100514)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 223 sites in United States, Canada and 10 more
- Volunteers
- 746 people
- Sponsor
- Pfizer